Condition: Pituitary · Pain, Postoperative · Sponsor: Hamilton Health Sciences Corporation
To assess the benefit of using an additional nerve block during minimally invasive pituitary surgery, to improve pain management after surgery. The medication (Bupivacaine) or a placebo (saline) will be injected during surgery and patients will be asked about their level of pain at multiple time points in the first 24 hours following surgery. Some patients will be randomized to a third, sham group that do not receive any additional injection. The aim is to improve patient outcomes and reduce the need for pain medication after surgery.
This description comes directly from the study's public registry record.
Dr. Kesava Reddy, MD · 905-521-2100 · reddy@hhsc.ca
Ms. Jessy Moore, MSc · 289-686-8827 · moorej@hhsc.ca
Always discuss trial participation with your own doctor first.
| Hamilton General Hospital | Hamilton, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06353529